$0.0 (0.76%)
| Source | Headline |
|---|---|
|
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and reported financial results for the first quarter ended March 31, 2026. globenewswire.com - 2026-05-07 16:05:00 |